The purpose of this study is to evaluate an experimental drug called camizestrant in people diagnosed with estrogen receptor-positive, human epidermal growth factor receptor 2- negative (ER+/HER2-) early-stage breast cancer who have an intermediate or high risk of recurrence and no evidence of disease following surgery. Camizestrant is a type of endocrine therapy (also called an oral selective estrogen receptor degrader), which is taken as a daily pill. Breast cancers that use estrogen to grow are called hormone receptor-positive and consist of cells with many receptors in them called estrogen receptors. Using these receptors, estrogen attaches to the breast cancer cells and sends messages, which tell the cancer cells to continue growing and multiplying. Camizestrant works by breaking down the estrogen receptors in cells. It also works by binding to the estrogen receptors and blocking them from being triggered by estrogen, which may help stop the patient’s cancer from coming back. Several studies demonstrated that camizestrant was superior to the current standard care endocrine therapy in advanced-stage breast cancer. Researchers aim to determine whether treatment with camizestrant is better at preventing disease recurrence (disease that comes back) than standard endocrine therapy (letrozole, anastrozole, exemestane or tamoxifen) in high risk early-stage breast cancer. Another drug, abemaciclib, may be added to camizestrant and endocrine therapy per the study doctor’s choice and local standard of care.

• CS Cancer at Cedars-Sinai Medical Center : Nikki Kem-Bernard
• Hunt Cancer Institute, an Affiliate of Cedars-Sinai Cancer